Immunocore Holdings plc (IMCR): Capital Expenditures
$4.34M
Year ended 2025-12-31
$6.20M
Trailing 12 months to 2026-06-30
+25.4%
3-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.34M | -16.1% | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | $5.17M | -4.6% | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | $5.42M | +146.3% | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | $2.20M | +58.9% | 2025-02-26, From 2022-01-01 |
| 2021-12-31 | $1.39M | n/a | 2024-02-28, From 2021-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $4.34M | -16.1% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $11.95M | +182.0% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | $28.00M | +451.7% |
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | $9.86M | +529.2% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $22.57M | +174.4% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $2.96M | -19.2% |
| Vericel Corp (VCEL) | 2025-12-31 | $27.16M | -57.5% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $33.84M | +205.7% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $145.0K | -73.8% |
Compare IMCR, KRYS, TWST, TARS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗